OR WAIT 15 SECS
The author discusses the risks involved with aseptic processing, methods and tools used to identify and control risk, and regulatory guidelines relevant to the risk-management process.
This article is part of PharmTech's supplement "Injectable Drug Delivery."
Aseptic processes are some of the most difficult processes to conduct in the pharmaceutical industry. Because of the nature of aseptic processes, sterile products produced aseptically present a significantly higher risk to the patient than terminally sterilized products. Because of the high level of risk, an effective quality-risk-management program is necessary to protect the patient. An effective risk-management program aids in the careful control of the process, reducing the risk of contamination as well as wasted effort in controlling insignificant risks.
What is an aseptic process?
Aseptic processing involves manipulation of sterile components in a carefully controlled environment using careful techniques to produce a sterile product. While aseptic processing usually involves filling of final drug product, there are other types of aseptic processes, including aseptic assembly of devices or combination products, aseptic crystallization or aseptic precipitation of drug product to produce a sterile bulk-drug substance, and aseptic formulation of final drug product.
One thing all aseptic processes have in common is their high level of risk. They require careful control of the aseptic environment, of personnel practices and procedures, sterilization of equipment and components, extensive environmental monitoring, and many other controls. The number of controls required and the severe consequences of control failure make aseptic processing one of the highest-risk pharmaceutical processes. Quality risk management is an essential tool in ensuring product quality.
Quality risk management
Although quality risk management (QRM) is a relatively new concept to the pharmaceutical industry, it has been used in other industries for many decades, with some risk-assessment tools dating back to the World-War-II era. The pharmaceutical industry has been slow to adopt many of these tools because of the industry focus on regulatory compliance as the driving force for quality. This traditional compliance-based approach had its drawbacks that became more evident as the industry became more diverse and sophisticated. A "one-size-fits-all" approach to quality became increasingly unworkable, leading the US Food and Drug Administration to develop a quality systems approach to regulation.
The quality systems approach to the pharmaceutical industry was launched on a large scale with the FDA publication of Pharmaceutical CGMPs for the 21st Century—A Risk Based Approach in August 2002 (1). This initiative had the ambitious goal of transforming the FDA regulatory approach to the pharmaceutical industry into a science-based and risk-based approach with an integrated quality systems orientation.
In the time since the publication of the concept paper, this initiative has been largely successful, leading to publication of international guidance documents such as ICH Q9 Quality Risk Management, and the Parenteral Drug Association (PDA) Technical Report No. 44 on Quality Risk Management for Aseptic Processes (2, 3). The publication of ICH Q10 Pharmaceutical Quality System has further enhanced the risk-based approach to pharmaceutical manufacturing.
There are many potential uses for quality risk management in the pharmaceutical industry, including:
The uses for quality-risk-management tools are nearly limitless. A few examples of the uses of these tools in aseptic processing include:
What is quality risk management?
Risk is the combination of the probability of harm and the severity of harm. For the purposes of QRM, it is the risk to the patient that is important, not the risk to other stakeholders such as government, industry, medical practitioners, etc.
According to ICH Q9, quality risk management is defined as "a systematic process for the assessment, control, communication, and review of risks to the quality of the drug product across the product lifecycle" (2).
Some key concepts in this definition are that QRM is a systematic process, and that it is designed to manage the risks to product quality across the product lifecycle. The introduction of a systematic process for managing product quality is crucial to consistently providing a high-quality product to the customer.
ICH Q9 defines the two primary principles of quality risk management as follows:
These principles lead to a need for a formal risk-management program for manufacturers of parenteral products. Because these products, which include most biotechnology-derived drugs, bypass many of the body's defense systems, the level of risk to the patient is significantly higher than in oral or topical products.
The quality-risk-management process
ICH Q9 describes the quality risk-management process. Figure 1 illustrates the components of the quality risk-management process across the product lifecycle.
Figure 1: Risk-management process (2). (FIGURE 1 IS COURTESY OF ICH)
Risk assessment. Risk assessment is the first portion of the quality-risk-management process. It consists of identifying potential hazards, analyzing hazards, and risks associated with exposure to those hazards. A few key points about the risk assessment process include:
The output of the risk-assessment portion of the risk-management process is used in the risk-control portion of the risk-management process.
Risk control. Risk control consists of developing a plan to reduce and/or accept risks. The purpose of risk control is to reduce risk to an acceptable level. The formality and effort of risk control should be appropriate for the level of risk. The following questions should be asked during this phase:
A risk control plan may be the output of the risk control process. This plan may be included in a project plan or validation master plan, as part of the risk-communication process.
Risk communication. Risk communication is simply that—the communication of risks between decision makers and other interested parties, either within or outside the company. This may be done formally or informally, as appropriate for the risk level of the product and process.
Risk review. Risk review is simply periodic review of risks as part of the ongoing quality management process. Examples of where formal or informal risk review might be performed include periodic management review, as part of a change control program or as part of annual product reviews. However it is performed, risk review should be integrated into the quality-management system.
The following is a partial list of some of the risk-assessment tools used in the pharmaceutical industry. This is hardly a comprehensive list. There are numerous risk-assessment tools available in different industries and for different functions within the same industry.
3-D risk assessment. Three-dimensional (3-D) risk assessment is a risk assessment tool that takes into account a system's distance from the process stream, its location along the process stream (e.g., active pharmaceutical ingredient [API] synthesis, and purification, bulk product formulation, sterile filtration, filling and stoppering, etc.), and the system's complexity (4). This tool is mainly used to assign a risk level to an overall system. Where appropriate, additional risk assessment tools may be used to evaluate risks within a pharmaceutical system. Figure 2 gives a visual representation of the 3-D risk assessment process for a biotechnology-derived product (4).
Figure 2: 3-D risk assessment matrix (4). (FIGURE 2 IS COURTESY OF THE AUTHOR)
Failure mode and effects analysis. Failure mode and effects analysis (FMEA) is one of the most commonly used methods for pharmaceutical risk assessment. It is a team-based structured risk assessment method that can assign a numerical risk priority number based on relative perceived risk. A FMEA is dependent on the expertise of the team members (see Table I).
Table I: Sample FMEA for fill line change over.
Hazard analysis and critical control points. Hazard analysis and critical control points (HACCP) is a tool mandated by FDA's Center for Food Safety and Applied Nutrition for use in the seafood industry and other food processing industries. Its use in the pharmaceutical industry was described in detail by the World Health Organization (WHO) in 2003 (5). The seven principles of HACCP include:
Table II illustrates an HACCP worksheet for the filling of product into vials for a hypothetical biotech company.
Table II: HACCP worksheet (adapted from FDA CFSAN website).
Fault tree analysis. Fault tree analysis (FTA) is a risk-assessment method that begins with a failure event, and uses logic diagrams to determine the sequence of events required to cause the failure. FTA is frequently used as a design tool for critical systems. FTA can be used with other tools such as FMEA to ensure all failure modes are included and to develop estimates of the frequency of a particular failure mode.
This tool is excellent for equipment design and commissioning, for determining procedural controls needed to prevent a failure event, and for determining qualification and control strategies. With modification, it can also be used to assign probabilities to each failure mode.
The limitation of this tool is that it requires a large amount of time and effort to construct properly; it can expand rapidly as more detail is added. It is more suitable for large, complex systems than for simple systems because of the time and effort required.
FTA involves the following steps:
Figure 3 shows a partial fault tree diagram for a critical failure—cross-contamination between two products. The top event represents the failure. Each subsequent level is connected by a logic gate (AND, OR, etc.). As shown in this figure, a fault tree diagram can grow rapidly and can become quite complex.
Figure 3: Fault tree analysis diagram. (FIGURE 3 IS COURTESY OF THE AUTHOR)
Implications of risk assessment on processing
When a process step or other activity is determined to be high risk, what should be done? These determinations should cause initiation of project activities to reduce the risk level. However, if reduction is not possible, there should be additional in-process controls, additional testing, additional training, and so on. In summary, the organization should expend additional effort to mitigate or control the risk situation. At the same time, efforts on processes or activities that are well controlled or do not represent risk can be minimized. For example, a new purified water (PW) supply was planned for an aseptic processing facility. This PW supply was to be used as feed water for a water-for-injection (WFI) still, for initial rinse water for clean in place (CIP) of formulation and filling equipment, and for make-up of wash solutions for CIP of formulation and filling equipment. WFI was used for the final rinse of this equipment. Based on these parameters, a 3-D risk assessment was performed on the PW system, giving the results shown in Table III.
Table III: 3-D risk assessment for purified water system.
The overall score determined by this risk assessment is 30, indicating the overall risk is low to medium. This low overall score indicates that detailed formal risk assessment methods such as FMEA are not needed for this system. While the overall risk score indicates few controls are needed, the distance along product stream score indicates that some engineering controls and in-process controls are justified. Based on this analysis, the design engineer decides to add an ultraviolet (UV) system for controlling bioburden, as well as conductivity alarms to indicate system problems. In addition, periodic monitoring and trending of system bioburden is justified.
A contrasting example would be an aseptic filler intended for multiproduct use. This filler is designed for high-speed filling and stoppering of several different products with rapid changeover. This filler is designed for in-line check weighing, and for automated CIP and sterilization in place (SIP). A 3-D risk assessment of this equipment gave the results shown in Table IV.
Table IV: 3-D risk assessment for aseptic filler.
The risk assessment clearly indicates the filler is a high risk system. Based on this assessment, design and process FMEAs were performed on the filler to identify controls to mitigate high-risk items. Table V is a partial example of a process FMEA used to identify design controls for the new filler.
Table V: Process FMEA example (system=aseptic filler; process=clean-in-place).
This example shows a small portion of a detailed FMEA for the CIP process for a critical system (aseptic filler). A FMEA such as this one could be used to put additional controls into place during design of the system, as well as to identify critical items that need to be verified during validation.
Implications of risk determination on validation
What are the implications of high-risk processes or activities on validation? When validating high-risk processes or activities, there should be proportionately increased sampling, testing, or more rigorous acceptance criteria to provide greater assurance of process acceptability. The 2008 FDA process validation draft guidance specifically incorporates the following risk management principles:
The European Union's Guide to Good Manufacturing Practice, "Annex 15," also refers to the use of risk management in validation and states, "Significant changes to the facilities, the equipment, and the processes, which may affect the quality of the product, should be validated. A risk assessment approach should be used to determine the scope and extent of validation" (7).
How is risk management incorporated into validation? Risk-assessment tools are used to determine the extent of validation and frequency of validation. A few practical examples of how risk-management tools are used in validation may be helpful.
Low-risk system. A chilled water system was used to cool a jacketed tank during formulation of a product prior to sterile filtration. This system contacts the tank jacket only. The chilled water system was controlled by an off-the-shelf temperature control system with a chart recorder. A 3-D risk assessment of the chilled water system gave the results shown in Table VI.
Table VI: 3-D risk assessment-low risk system.
Because the system is low risk, no qualification was necessary beyond engineering commissioning of the system. Once commissioned, the system was placed under a standard PM program, and the chart recorder and temperature controller were calibrated on an annual basis.
Medium-risk system. A bulk formulation tank was used to compound a parenteral product before sterile filtration. This tank was connected to a distributed control system (DCS) that controls mixing speed and temperature according to setpoints entered by the operator from a local panel in the compounding area. Ingredients other than WFI were added manually by the operators. WFI was added from a WFI drop at the mixing tank, which was opened by the operator from the DCS local panel. A level transmitter connected to the tank indicates the volume of WFI added to the tank. A 3-D risk assessment of the formulation tank gave the results shown in Table VII.
Table VII: 3-D risk assessment-medium risk system.
Based on the risk score of 60, the system was designated as a medium-risk system. Construction and operation of the formulation tank were verified under installation qualification (IQ) and operational qualification (OQ) protocols. The compounding process itself was verified under a performance qualification (PQ) protocol. After completing IQ, OQ, and PQ, the formulation tank was placed under change control. No periodic requalification was required, but periodic assessment of the system was required to ensure it maintained its validated state of control.
High-risk system. An injectable protein therapeutic was not stable in liquid form and requires lyophilization. The lyophilizer was highly automated, with automated CIP and SIP, automated moisture content and product temperature monitoring using pressure rise methodology, and a supervisory control and data acquisition system containing the lyophilization recipes for each dosage form of the product. Product was loaded into the lyophilizer by an autoloading system. A 3-D risk assessment of the lyophilizer gave the results shown in Table VIII.
Table VIII: 3-D risk assessment-high-risk system.
Based on the risk score of 125, the lyophilizer was designated a high-risk system. Extensive validation efforts, including computerized system validation (CSV), CIP, and SIP validation, IQ and OQ including shelf mapping, condenser capacity and sublimation rate, and other tests were performed to characterize the performance of the lyophilizer. PQ of the lyophilizer included surrogate lots with site-specific sampling for moisture content, cake appearance and reconstitution, followed by media fills and conformance lots for the protein therapeutic. The lyophilizer was placed under change control with periodic requalification, including shelf mapping and requalification of the CIP and SIP processes. Media fills were performed using the lyophilizer on a quarterly basis.
Quality risk management is an essential tool for qualification of aseptic processes. It is not just a tool for CGMP compliance; it offers real benefits to the validation process by identifying risks and ensuring that critical risks are controlled. By focusing managing risks to the patient, pharmaceutical manufacturers can ensure that the right resources are applied at the right place at the right time—improving patient safety while eliminating unnecessary validation efforts.
Ed White is a QA validation specialist at Baxter Healthcare Corporation, 1700 Rancho Conejo Blvd., Thousand Oaks, CA, 805.375.6779, firstname.lastname@example.org. This article was first published in The Journal of Validation Technology, Vol. 15, Num. 2, Spring 2009.
1. FDA, Pharmaceutical CGMPs for the 21st Century—A Risk Based Appoach (Rockville, MD, Aug. 2002).
2. ICH Q9 Quality Risk Management, Nov. 9, 2005.
3. PDA, Technical Report No. 44, Quality Risk Management for Aseptic Processes, 2008 Supplement, Volume 62, No. S-1.
4. Oliver, James, J. of Valid. Technol., 14, (5), Autumn 2008.
5. WHO, Annex 7: Application of Hazard Analysis and Critical Control Point (HACCP) Methodology to Pharmaceuticals, WHO Expert Committee on Specifications for Pharmaceutical Preparations, Thirty-Seventh Report, Geneva, Switzerland, 2003.
6. FDA, Draft Guidance for Industry—Process Validation: General Principles and Practices (Rockville, MD, Nov. 2008).
7. European Commission, Enterprise Directorate—General, Working Party on Control of Medicines and Inspections, Final Version of Annex 15 to the EU Guide to Good Manufacturing Practice: Qualification and Validation, Sept. 2001.